The FDA label carries a boxed warning for cytokine release syndrome (CRS), which is a systemic response to the activation and proliferation of CAR-T cells causing high fever and flu-like symptoms, and for neurologic toxicities. Both cytokine release syndrome and neurologic toxicities can be fatal or life-threatening. The most common side effects of<unk>  include serious infections, low blood cell counts and a weakened immune system. Side effects from treatment usually appear within the first one to two weeks after treatment, but some side effects may occur later. The most common Grade 3 or higher reactions were anemia, neutropenia, thrombocytopenia, hypotension, hypophosphatemia, encephalopathy, leukopenia, hypoxia, pyrexia, hyponatremia, hypertension, infection – pathogen unspecified, pneumonia, hypocalcemia, and lymphopenia. Because of the risk of cytokine release syndrome and neurological toxicities,<unk>  was approved with a risk evaluation and mitigation strategy (REMS), which includes elements to assure safe use. The risk mitigation measures for<unk>  are identical to those of the REMS Program for another CAR-T therapy, axicabtagene ciloleucel (Yescarta).
Brexucabtagene autoleucel
Ciltacabtagene autoleucel
Lisocabtagene maraleucel
Belantamab mafodotin
Idecabtagene vicleucel
Levomilnacipran
Nicogel
Dotinurad